A genuine biological puzzle underlies this story. Average testosterone levels in young men have fallen sharply over the past two decades, from 605 nanograms per deciliter in 1999-2000 to 451 in 2015-2016. It is a legitimate public health question why younger cohorts start with lower baselines than their fathers. Yet what might be a straightforward medical conversation about declining population health has been colonised by a very different narrative: one of panic, personal inadequacy, and commercial opportunity.
A new study from the University of Sydney found that influencer marketing on platforms like TikTok reframes everyday experiences like fatigue, stress and lower libido as testosterone 'deficiency' requiring medical intervention, with posts encouraging men to seek testing and positioning private clinics as faster and more effective than conventional healthcare. This is not public health messaging. This is salesmanship dressed in scientific language.
The research found the content was closely linked to online manosphere communities that promote narrow, hyper-masculine ideals and frame men's health through dominance and physical strength, with health misinformation increasingly featuring testosterone marketing. The underlying argument reduces manhood itself to a measurable hormone level; restore the number, the narrative goes, and you restore yourself.
There is a logical trap here worth examining. Population testosterone is genuinely declining. Yet the rate of actual testosterone deficiency does not match the scale of pharmaceutical uptake. A widely cited statistic estimates that 20 percent of men aged 15 to 39 have low testosterone, but this misleading range groups teenagers with men in their late 30s, and true deficiency in men under 30 may be closer to 10-15 percent. Even so, social media marketing makes younger men feel they are part of an epidemic. The crisis is real on screens; the scale of actual need is smaller.
The medical case for testosterone replacement in truly deficient men is defensible. Recent clinical trials have provided reassurance that for men who clearly have testosterone deficiency, there is no apparent increased risk of heart attack or stroke from testosterone replacement therapy. Yet this caveat—"for men who clearly have deficiency"—is precisely where private clinics and influencers slip away from evidence. They market it as an optimisation product; normal ageing becomes a condition needing treatment.
Evidence shows some people are undergoing testosterone replacement therapy even when they do not have clinically low levels, and taking testosterone can suppress the body's own production by shutting down the hypothalamic-pituitary-gonadal axis controlling testosterone and sperm production. This creates a dependency. The biggest concern with starting testosterone therapy too early is that it can interfere with the body's own hormone production; for a healthy man in his early 20s sitting around 400 nanograms per deciliter, a prescription might raise him to 800, but then when he reaches 45, levels worsen without intervention, potentially locking him into lifelong medication.
Known risks include decreased fertility and sperm count, elevated blood counts which can lead to blood clots if not monitored, acne, breast enlargement, and hot flashes. These are not trivial side effects to accept for the sake of feeling subjectively more energetic. For younger men especially, the trade-off between short-term mood improvement and decades of potential medical dependency is asymmetrical.
The legitimate counter-argument is straightforward: if testosterone truly improves quality of life for men who are genuinely deficient and have exhausted lifestyle interventions, then access matters. For men under 30, lifestyle changes are usually the most powerful and safest intervention, including regular exercise, balanced nutrition, consistent sleep, and stress reduction. Yet these are precisely what the online wellness industry deflates in favour of immediate pharmaceutical solutions. A product you swallow is more profitable than advice to exercise more and sleep better.
What Australian observers often miss is how these narratives exploit genuine anxieties about masculinity and status in changing times. Younger men do face real pressures. The solution marketed to them, however, addresses the anxiety rather than its cause. It is easier to inject testosterone than to examine why so many feel inadequate without it. It is easier to target the glands than the culture that makes men feel their glands have failed them.
The evidence suggests a pragmatic middle ground. Low testosterone is defined as a total testosterone measurement below 300 nanograms per deciliter, distinguished from hypogonadism, which involves both low testosterone and specific clinical symptoms. Medical treatment should follow actual diagnosis backed by repeat testing, not algorithmic social media marketing. And for the population-level decline in testosterone? That deserves investigation into the environmental and lifestyle factors driving it, not a privatised rush to medicate away the symptom.